UM
Affiliated with RCfalse
Status已發表Published
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Xu, Kun1; Gao, Ping2,3; Liu, Sheng4; Lu, Shuaiyao5; Lei, Wenwen6; Zheng, Tianyi7; Liu, Xueyuan8; Xie, Yufeng9; Zhao, Zhennan2,3; Guo, Shuxin10; Tang, Cong5; Yang, Yun5; Yu, Wenhai5; Wang, Junbin5; Zhou, Yanan5; Huang, Qing5; Liu, Chuanyu11; An, Yaling12; Zhang, Rong11; Han, Yuxuan12; Duan, Minrun13; Wang, Shaofeng2,3; Yang, Chenxi2,3; Wu, Changwei14; Liu, Xiaoya14; She, Guangbiao14; Liu, Yan15; Zhao, Xin2; Xu, Ke6; Qi, Jianxun2; Wu, Guizhen6; Peng, Xiaozhong5,16; Dai, Lianpan2,3; Wang, Peiyi4; Gao, George F.1,2,3,12
2022-06-23
Source PublicationCell
ISSN0092-8674
Volume185Issue:13Pages:2265-2278.e14
Abstract

Breakthrough infections by SARS-CoV-2 variants become the global challenge for pandemic control. Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. Here, we developed a chimeric RBD-dimer vaccine approach to adapt SARS-CoV-2 variants. A prototype-Beta chimeric RBD-dimer was first designed to adapt the resistant Beta variant. Compared with its homotypic forms, the chimeric vaccine elicited broader sera neutralization of variants and conferred better protection in mice. The protection of the chimeric vaccine was further verified in macaques. This approach was generalized to develop Delta-Omicron chimeric RBD-dimer to adapt the currently prevalent variants. Again, the chimeric vaccine elicited broader sera neutralization of SARS-CoV-2 variants and conferred better protection against challenge by either Delta or Omicron SARS-CoV-2 in mice. The chimeric approach is applicable for rapid updating of immunogens, and our data supported the use of variant-adapted multivalent vaccine against circulating and emerging variants.

KeywordCovid19 Vaccine Delta Variant Immunogen Structure Omicron Variant Rbd Receptor-binding Domain Sars-cov-2 Vaccine Protection Variant Of Concern Voc
DOI10.1016/j.cell.2022.04.029
URLView the original
Indexed BySCIE
Language英語English
WOS Research AreaBiochemistry & Molecular Biology ; Cell Biology
WOS SubjectBiochemistry & Molecular Biology ; Cell Biology
WOS IDWOS:000823647900001
Scopus ID2-s2.0-85130405575
Fulltext Access
Citation statistics
Cited Times [WOS]:4   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionUniversity of Macau
Corresponding AuthorWu, Guizhen; Peng, Xiaozhong; Dai, Lianpan; Wang, Peiyi; Gao, George F.
Affiliation1.Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, 100101, China
2.CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China
3.University of Chinese Academy of Sciences, Beijing, 100049, China
4.Cryo-EM Center, Southern University of Science and Technology, Shenzhen, 518055, China
5.National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, 650031, China
6.NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China
7.Zhejiang University School of Medicine, Hangzhou, 310058, China
8.School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China
9.Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China
10.Faculty of Health Sciences, University of Macau, Macau, SAR, 999078, Macao
11.State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Guangxi University, Nanning, 530004, China
12.Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, China
13.School of Life Sciences, Yunnan University, Kunming, 650091, China
14.Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Hefei, 230088, China
15.Chongqing Medleader Bio-Pharm, Chongqing, 401338, China
16.State Key Laboratory of Medical Molecular Biology, Department of Molecular Biology and Biochemistry, Institute of Basic Medical Sciences, Medical Primate Research Center, Neuroscience Center, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, 100005, China
Recommended Citation
GB/T 7714
Xu, Kun,Gao, Ping,Liu, Sheng,et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2[J]. Cell,2022,185(13):2265-2278.e14.
APA Xu, Kun.,Gao, Ping.,Liu, Sheng.,Lu, Shuaiyao.,Lei, Wenwen.,Zheng, Tianyi.,Liu, Xueyuan.,Xie, Yufeng.,Zhao, Zhennan.,Guo, Shuxin.,Tang, Cong.,Yang, Yun.,Yu, Wenhai.,Wang, Junbin.,Zhou, Yanan.,Huang, Qing.,Liu, Chuanyu.,An, Yaling.,Zhang, Rong.,...&Gao, George F..(2022).Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.Cell,185(13),2265-2278.e14.
MLA Xu, Kun,et al."Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2".Cell 185.13(2022):2265-2278.e14.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Xu, Kun]'s Articles
[Gao, Ping]'s Articles
[Liu, Sheng]'s Articles
Baidu academic
Similar articles in Baidu academic
[Xu, Kun]'s Articles
[Gao, Ping]'s Articles
[Liu, Sheng]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Xu, Kun]'s Articles
[Gao, Ping]'s Articles
[Liu, Sheng]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.